SPY упал на премаркете

Ближайший уровень поддержки по SPY – 199.50 уровень сопротивления – 200.30



COST покупка при ужержании 125

EMES покупка выше 125

EGN смотрим на разворот

Gapping up/down: BLOX +13% and AMBA +9% after earnings, PRAN +28% after orphan designation status, CIEN +2% after upgrade; GPX -6% and FNSR -5% after earnings/SSS, KORS -5% after offering

Gapping up
In reaction to strong earnings/guidance: BLOX +13.4%, AMBA +9.3%, LOCO +2.9%, VRNT +2.6%.

Other news: PRAN +27.6% (received orphan designation status for its product for the treatment of Huntington's disease), HART +13.7% (received orphan designation status for its inBreath airway transplant system to restore the structure and/or function of the trachea subsequent to tracheal damage due to cancer, injury or infection), NSPH +10.8% (has engaged Jefferies LLC as its financial advisor to assist it in the development and evaluation of a full range of potential strategic alternatives for the Company), TASR +6% (higher following announcement that the NYPD will begin a pilot program of equipping officers with body cameras), OMED +4.1% (FDA removes partial clinical hold on OncoMed's ipafricept), ICLD +2.8% (announces multi-site deployment of security and threat prevention solutions and services for a large global consulting firm), MOBI +2.6% (announces repurchase of 16 mln shares from Sequoia Capital ), GPRO +1.7% (up in sympathy following supplier AMBA earnings), DGLY +1.5% (cont usual volatility pre-mkt), JOY +1% (positive Barron's mention), SD +0.8% ( announces $200 mln share repurchase program)


Analyst comments: IPCI +3.7% (upgraded to Buy at Maxim Group), VRTX +2.3% (upgraded to Buy from Neutral at Goldman), CIEN +1.8% (upgraded to Buy from Neutral at Goldman), ICPT +1.8% (initiated with an Outperform at Cowen), MTRX +1.7% (upgraded to Overweight from Equal Weight at First Analysis Sec), SNDK +1.5% (upgraded to Overweight from Equal-Weight at Morgan Stanley), BLUE +1.4% (initiated with a Buy at Sun Trust Rbsn Humphrey), INSM +1.4% (initiated with an Outperform at Cowen), MBLY +1.4% (target raised to $52 at RBC Capital Mkts), IL +1.1% (upgraded to Buy at Stifel ), ING +1% (upgraded to Overweight from Equal Weight at Barclays), BEAV +1% (upgraded to Buy from Hold at Deutsche Bank), BP +0.9% (upgraded to Buy from Neutral at Citigroup), QGEN +0.6% (upgraded to Buy from Sell at DZ Bank)

Gapping down
In reaction to disappointing earnings/guidance: ZQK -12.4%, GPS -5.8%, ZUMZ -5.1%, FNSR -5%, SEAC -4.3%, BEBE -2.8%, BEBE -2.8%, COO -2.1%.

Other news: REPH -40.5% (announced that the Phase 2b clinical trial of Dex-IN for the treatmnet of acute post-operative pain is not expected to reach statistical significance at its current design), KORS -5.1% (Michael Kors files for ordinary share shelf offering by selling shareholders; launches secondary public offering of ordinary shares on behalf of Sportswear, one of its principal founding shareholders, for the offering of 11,629,627 ordinary shares), TUMI -4.4% (announced secondary offering of 8 mln shares of common stock by Doughty Hanson & Co. Managers Limited), PNNT -4% ( announces public offering of 11 mln shares of common stock), GLNG -3.5% (announces secondary offering of ~27.83 mln shares of its common stock by World Shipholding Ltd.), HMY -2.5% (still checking), ST -2.2% (announced offering of ~15.05 mln ordinary shares by selling shareholders), CX -2% (prices of €400 mln and $1.1 bln in Senior Secured Notes), SDRL -1.7% (still checking), AU -1.6% (still checking), GSK -1.5% (will not be able to fill all demand for flu vaccines, according to reports), GTAT -1.3% (cont vol due to speculation surrounding iPhone component), SHPG -1% (still checking).

Analyst comments: TTWO -1.3% (downgraded to Neutral from Buy at Sterne Agee), CS -1.1% (downgraded to Neutral from Buy at UBS), PCLN -0.7% (downgraded to Equal Weight from Overweight at Evercore ), MS -0.7% (downgraded to Neutral from Outperform at Macquarie).

Оригинал статьи: gtstocks.com/analytics-05-09-2014.html